Society of Hematologic Oncology (SOHO) President Jennifer Brown, MD, PhD, of the Dana-Farber Cancer Institute and Harvard Medical School, discusses what she sees as the major highlights in chronic lymphocytic leukemia (CLL) from the Eleventh Annual Meeting of SOHO.
Dr. Brown highlighted sessions on Ritcher’s transformation and Bruton’s tyrosine kinase (BTK) inhibitors.
“We just had some very interesting Meet the Professor sessions where we were talking about BTK inhibitors and mechanisms of resistance with mutations, and that’s a very hot topic right now because the newer drug pirtobrutinib has a novel mechanism,” she said.
She also spoke about a debate on using measurable residual disease to guide duration of frontline therapy with venetoclax in CLL.
“I’m very interested to see what people have to say in that debate,” Dr. Brown said.